304 related articles for article (PubMed ID: 25932536)
1. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
Pahk K; Kim S; Choe JG
Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
[TBL] [Abstract][Full Text] [Related]
2. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG
Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
4. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
5. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
6. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
8. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
10. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
12. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
15. Integrated
Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
17. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
18. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
Pengel KE; Koolen BB; Loo CE; Vogel WV; Wesseling J; Lips EH; Rutgers EJ; Valdés Olmos RA; Vrancken Peeters MJ; Rodenhuis S; Gilhuijs KG
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1515-24. PubMed ID: 24777490
[TBL] [Abstract][Full Text] [Related]
19. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
